drugset / Trial / NCT06158139
Autologous CAR-T Cells Targeting B7-H3 in PDAC
Phase 1
Recruiting
27 enrolled
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this gene therapy research study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9.CAR.B7-H3 T cells) in patients with pancreatic ductal adenocarcinoma that came back after receiving standard therapy for this cancer. The iC9.CAR.B7-H3 treatment is experimental and has not been approved by the Food and Drug Administration.
Timeline
- Start
- 2024-07-18
- Primary completion
- 2028-04
- Completion
- 2030-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | iC9-CAR.B7-H3 T cells | Cell therapy | 1e+06 cells/kg | Intravenous |